A Study of LP-168 in Healthy Volunteers

Inclusion Criteria: * Subjects have no history of serious digestive system, central nervous system, cardiovascular system, kidney, respiratory system, metabolism and endocrine, skeletal and muscular system, blood system disease and cancer * Subjects (including partners) are willing to take effective contraception measures during study and within 3 months after last dose * Male and female healthy subjects aged 18 to 55 years old * Male subjects weigh ≥ 50 kg, and female subjects weigh ≥ 45 kg * Subjects able to understand and comply with study requirements * Willing to sign the informed consent Exclusion Criteria: * Abnormal vital signs, physical examination or laboratory tests with clinical significance * Abnormal ECG or echocardiography with clinical significance * Hepatitis B virus, Hepatitis C virus, HIV and syphilis test positive. COVID-19 DNA positive. * Subjects who have taken any drugs or health care products within 14 or 28 days before administration the study drug * Subjects who have consumed diets that may alter the activity of liver metabolic enzymes within 7 days before administration the study drug * Subjects who have consumed tea or alcohol-containing food product within 24hrs before administration the study drug * Subjects who have a history of dysphagia or condition may affect drug absorption, distribution, metabolism and excretion * Female subjects are breastfeeding or pregnant * Subjects who have a history of drug/ alcohol/ tobacco abuse * Subjects who have had a blood donation or massive blood loss within three months before screening; or had surgery within six months before screening * Subjects who have participated in other clinical trial within three months before screening * Subjects have special dietary requirements or cannot tolerate a standard meal